Price
CHART BY
Frequently asked questions
What is Revance's market capitalization?
The market capitalization of Revance is $378.94M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Revance?
Revance's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.923. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Revance's stock?
Currently, 6 analysts cover Revance's stock, with a consensus target price of $4.47. Analyst ratings provide insights into the stock's expected performance.
What is Revance's revenue over the trailing twelve months?
Over the trailing twelve months, Revance reported a revenue of $247.00M.
What is the EBITDA for Revance?
Revance's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$159.93M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Revance?
Revance has a free cash flow of -$194.91M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Revance have, and what sector and industry does it belong to?
Revance employs approximately 597 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Revance's shares?
The free float of Revance is 95.25M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $378.94M
- EPS (TTM)
- -$1.923
- Free Float
- 95.25M
- Revenue (TTM)
- $247.00M
- EBITDA (TTM)
- -$159.93M
- Free Cashflow (TTM)
- -$194.91M
Pricing
- 1D span
- $3.621$3.657
- 52W span
- $2.30$7.56
Analyst Ratings
The price target is $4.47 and the stock is covered by 6 analysts.
Buy
0
Hold
6
Sell
0
Information
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.
- Employees
- 597
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- US7613301099
- Primary Ticker
- RVNC